Page 38 - Hal Barron News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Subscribe Monoclonal antibodies: GSK and Vir to seek US approval for their COVID-19 candidate, EMA starts rolling review of Lilly's medicines By Jane Byrne GSK and its partner, Vir Biotechnology, report that their jointly developed monoclonal antibody, VIR-7831, reduces hospitalization and risk of death in early treatment of adults with COVID-19. A global phase 3 clinical trial, COMET-ICE, based its initial analysis on data from 583 patients at risk of hospital admission. The partners said VIR-7831 is a new treatment for ...

Advances in medicine to treat COVID and immunize the population have been astounding; more important developments this week

Based on the 'profound' results, the British pharmaceuticals company, led by chief exec Emma Walmsley (pictured), said it was urgently seeking approval from regulators for the antibody treatment.

A monoclonal antibody drug reduces hospital admission or death from Covid-19 by 85, the pharmaceutical giant GlaxoSmithKline (GSK) has announced.

Monoclonal antibodies are laboratory-produced molecules that mimic human antibodies.